News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK)'s R&D is Delivering, But the Street's Not Buying



7/26/2012 6:41:19 AM

One of the less endearing, if not outright annoying, traits of those who make up Wall Street is their tendency to harp on whatever a company doesn't have at the moment. In the case of Big Pharma, good current quarterly results are often waved off with skepticism about generic competition and/or the pipeline. For GlaxoSmithKline (GSK) it looks like the reverse is true. Forget the solid pipeline and good recent Phase 3 results, it's this quarter's bad performance that somehow proves Glaxo isn't a good company.

Read at Seeking Alpha
Read at Philadelphia Inquirer
Read at Reuters
Read at PharmaBiz


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES